Clinical pharmacology of levetiracetam for the treatment of epilepsy

References

• de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav.12(4), 540–546 (2008).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Emerging drugs for epilepsy. Expert Opin. Emerg. Drugs12(3), 407–422 (2007).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology60(11 Suppl. 4), S2–S12 (2003).
   PubMedGoogle Scholar
• Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol. Scand. Suppl.181, 30–35 (2005).
   PubMedGoogle Scholar
• Toledano R, Gil-Nagel A. Adverse effects of antiepileptic drugs. Semin. Neurol.28(3), 317–327 (2008).
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther.85(2), 77–85 (2000).
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet.43(11), 707–724 (2004).
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia49(7), 1239–1276 (2008).
   PubMed Web of Science ®Google Scholar
• Klitgaard H, Verdru P. Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin. Drug Discov.2(11), 1537–1545 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch BA, Lambeng N, Nocka K et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA101(26), 9861–9866 (2004).
   PubMed Web of Science ®Google Scholar
• Crowder KM, Gunther JM, Jones TA et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl Acad. Sci. USA96(26), 15268–15273 (1999).
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Gillard M, Leclercq K et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia DOI: 10.1111/j.1528-1167.2009.02089.x (2009) (Epub ahead of print).
   Google Scholar
• Lynch JM, Tate SK, Kinirons P et al. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res.83(1), 44–51 (2009).
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Matagne A, Leclercq K et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology54(4), 715–720 (2008).
   PubMed Web of Science ®Google Scholar
• Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther.284(2), 474–479 (1998).
   PubMed Web of Science ®Google Scholar
• Margineanu DG, Matagne A, Kaminski RM, Klitgaard H. Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. Brain Res. Bull.77, 282–285 (2008).
   PubMed Web of Science ®Google Scholar
• Yan HD, Ji-qun C, Ishihara K, Nagayama T, Serikawa T, Sasa M. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia46(8), 1170–1177 (2005).
   PubMedGoogle Scholar
• Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia41(10), 1276–1283 (2000).
   PubMed Web of Science ®Google Scholar
• Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik IE. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology55(2), 236–242 (2000).
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia41(9), 1179–1186 (2000).
   PubMed Web of Science ®Google Scholar
• Glauser TA, Ayala R, Elterman RD et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology66(11), 1654–1660 (2006).
   PubMed Web of Science ®Google Scholar
• Piña-Garza JE, Nordli D, Rating D et al. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia50(5), 1141–1149 (2009).
   PubMed Web of Science ®Google Scholar
• Tsai JJ, Yen DJ, Hsih MS et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia47(1), 72–81 (2006).
   PubMed Web of Science ®Google Scholar
• Heo K, Lee BI, Yi SD et al. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients. Seizure16(5), 402–409 (2007).
   PubMedGoogle Scholar
• Wu XY, Hong Z, Wu X et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Epilepsia50(3), 398–405 (2009).
   PubMed Web of Science ®Google Scholar
• Murasaki M, Yagi K, Yamauchi T et al. Multicentre, double-blind, randomised, placebo-controlled, parallel-group study of add-on levetiracetam in Japanese patients with uncontrolled partial seizures. 6th Asian and Oceanian Epilepsy Congress. Kuala Lumpur, Malaysia, 16–19 November 2006, Abstract Book 62-63 (2006) (Abstract 256).
   Google Scholar
• Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology68(6), 402–408 (2007).
   PubMed Web of Science ®Google Scholar
• Pohlmann-Eden B, van Paesschen W, Hallstrom Y et al. The KOMET study: an open-label, randomized, parallel-group trial comparing the efficacy and safety of levetiracetam with sodium valproate and carbamazepine as monotherapy in subjects with newly diagnosed epilepsy. Epilepsia49(Suppl. 7), 448–449 (2008).
   Google Scholar
• Noachtar S, Andermann E, Meyvisch P et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology70(8), 607–616 (2008).
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy; Levetiracetam N01057 Study Group. Neurology69(18), 1751–1760 (2007).
   PubMed Web of Science ®Google Scholar
• French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res.47(1-2), 77–90 (2001).
   PubMed Web of Science ®Google Scholar
• Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin. Ther.30(2), 260–270 (2008).
   PubMed Web of Science ®Google Scholar
• Levisohn PM, Mintz M, Hunter SJ, Yang H, Jones J; on behalf of the N01103 Levetiracetam Study Group. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebocontrolled, non-inferiority trial. Epilepsia (2009) (In Press).
   PubMedGoogle Scholar
• De La Loge C, Hunter S, Schiemann J, Yang H. Exploratory assessment of behavioral and emotional function in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized placebo-controlled trial. Neurology70(Suppl. 1), A74 (2008).
   Google Scholar
• Strolin Benedetti M, Whomsley R, Nicolas JM, Young C, Baltes E. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur. J. Clin. Pharmacol.59(8–9), 621–630 (2003).
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin. Pharmacokinet.45(4), 351–363 (2006).
   PubMed Web of Science ®Google Scholar
• Coupez R, Straetemans R, Sehgal G, Stockis A, Lu ZS. Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets. J. Clin. Pharmacol.43(12), 1370–1376 (2003).
   PubMedGoogle Scholar
• Hirsch LJ, Arif H, Buchsbaum R et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia48(7), 1351–1359 (2007).
   PubMedGoogle Scholar
• Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia42(Suppl. 4), 24–27 (2001).
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Collart P, Gerin B et al.In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab. Dispos.27(2), 250–254 (1999).
   PubMed Web of Science ®Google Scholar
• Otoul C, De Smedt H, Stockis A. No evidence for pharmacokinetic interaction of levetiracetam with other antiepileptic drugs in Japanese and Western adults with epilepsy. Epilepsia47(Suppl. 3), 47 (2006).
   Google Scholar
• Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia48(11), 2111–2115 (2007).
   PubMed Web of Science ®Google Scholar
• Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res.46(2), 93–99 (2001).
   PubMed Web of Science ®Google Scholar
• Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res.47(1–2), 55–63 (2001).
   PubMed Web of Science ®Google Scholar
• Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia43(7), 697–702 (2002).
   PubMed Web of Science ®Google Scholar
• Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure9(2), 80–87 (2000).
   PubMed Web of Science ®Google Scholar
• Gidal BE, Baltès E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res.64(1–2), 1–11 (2005).
   PubMed Web of Science ®Google Scholar
• Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin. Pharmacokinet.46(6), 503–512 (2007).
   PubMed Web of Science ®Google Scholar
• Toublanc N, Sargentini-Maier M-L, Lacroix B, Jacqmin P, Stockis A. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin. Pharmacokinet.47(5), 333–341 (2008).
   PubMed Web of Science ®Google Scholar
• Fountain NB, Conry JA, Rodríguez-Leyva I et al. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Res.74(1), 60–69 (2007).
   PubMedGoogle Scholar
• French J. Use of levetiracetam in special populations. Epilepsia42(Suppl. 4), 40–43 (2001).
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin. Pharmacol. Ther.77(6), 529–541 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao Q, Jiang J, Li X, Lu ZS, Hu P. Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br. J. Clin. Pharmacol.63(5), 614–617 (2007).
   PubMed Web of Science ®Google Scholar
• Glauser TA, Mitchell WG, Weinstock A et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia48(6), 1117–1122 (2007).
   PubMed Web of Science ®Google Scholar
• Pellock JM, Glauser TA, Bebin EM et al. Pharmacokinetic study of levetiracetam in children. Epilepsia42(12), 1574–1579 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol.48, 303–332 (2008).
   PubMed Web of Science ®Google Scholar
• Toublanc N, Lovern M, Sargentini-Maier M-L, Stockis A. Population pharmacokinetic analysis of levetiracetam in pediatric patients with epilepsy aged 1 month to 16 years. Epilepsia50(Suppl. 4), 131 (2009).
   PubMedGoogle Scholar
• Adab N. Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful? CNS Drugs20(10), 791–800 (2006).
   PubMed Web of Science ®Google Scholar
• Brodtkorb E, Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure17(2), 160–165 (2008).
   PubMed Web of Science ®Google Scholar
• Westin AA, Reimers A, Helde G, Nakken KO, Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure17(2), 192–198 (2008).
   PubMed Web of Science ®Google Scholar
• Pennell PB, Koganti A, Helmers SL et al. The impact of pregnancy and childbirth on the elimination of levetiracetam. Epilepsia46(Suppl. 8), 89 (2005).
   PubMedGoogle Scholar
• Tomson T, Palm R, Kallen K et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia48(6), 1111–1116 (2007).
   PubMed Web of Science ®Google Scholar
• Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia46(5), 775–777 (2005).
   PubMed Web of Science ®Google Scholar
• Allegaert K, Lewi L, Naulaers G, Lagae L. Levetiracetam pharmacokinetics in neonates at birth. Epilepsia47(6), 1068–1069 (2006).
   PubMed Web of Science ®Google Scholar
• Rhodin MM, Anderson BJ, Peters AM et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol.24(1), 67–76 (2009).
   PubMed Web of Science ®Google Scholar
• Guo T, Oswald LM, Mendu DR, Soldin SJ. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry. Clin. Chim. Acta375(1–2), 115–118 (2007).
   PubMed Web of Science ®Google Scholar
• Jain DS, Subbaiah G, Sanyal M, Pal U, Shrivastav PS. Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. Rapid Commun. Mass Spectrom.20(17), 2539–2547 (2006).
   PubMed Web of Science ®Google Scholar
• Lancelin F, Franchon E, Kraoul L et al. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther. Drug. Monit.29(5), 576–583 (2007).
   PubMed Web of Science ®Google Scholar
• Martens-Lobenhoffer J, Bode-Boger SM. Determination of levetiracetam in human plasma with minimal sample pretreatment. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.819(1), 197–200 (2005).
   PubMed Web of Science ®Google Scholar
• Pucci V, Bugamelli F, Mandrioli R, Ferranti A, Kenndler E, Raggi MA. High-performance liquid chromatographic determination of levetiracetam in human plasma: comparison of different sample clean-up procedures. Biomed. Chromatogr.18(1), 37–44 (2004).
   PubMed Web of Science ®Google Scholar
• Rouits E, Burton I, Guenole E, Troenaru M, Stockis A, Sargentini-Maier M-L. Pharmacokinetics of levetiracetam XR 500 mg tablets. Epilepsy Res.84(2–3), 224–231 (2009).
   PubMed Web of Science ®Google Scholar
• Snoeck E, Stockis A. Dose–response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. Epilepsy Res.73(3), 284–291 (2007).
   PubMedGoogle Scholar
• Johannessen SI, Battino D, Berry DJ et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit.25(3), 347–363 (2003).
   PubMed Web of Science ®Google Scholar
• Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin. Pharmacokinet.45(11), 1061–1075 (2006).
   PubMed Web of Science ®Google Scholar
• Lins RL, Otoul C, de Smedt F, Coupez R, Stockis A. Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers. Int. J. Clin. Pharmacol. Ther.45(1), 47–54 (2007).
   PubMedGoogle Scholar
• Matías-Guiú J, Molins A, Mauri JA, Villar E. Acceptability and tolerability of levetiracetam as oral solution (the ‘Solucion’ study). Epilepsia48(Suppl. 6), 341 (2007).
   Google Scholar
• Ramael S, de Smedt F, Toublanc N et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin. Ther.28(5), 734–744 (2006).
   PubMed Web of Science ®Google Scholar
• Ramael S, Daoust A, Otoul C et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia47(7), 1128–1135 (2006).
   PubMed Web of Science ®Google Scholar
• Snoeck E, Jacqmin P, Sargentini-Maier ML, Stockis A. Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules. Epilepsy Res.76(2–3), 140–147 (2007).
   PubMed Web of Science ®Google Scholar
• Baulac M, Brodie MJ, Elger CE et al. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures. Epilepsia48, 589–592 (2007).
   PubMedGoogle Scholar
• Otoul C, Rouits E, Burton I et al. Single dose bioequivalence between levetiracetam 2 × 750 mg XR tablets and 3 × 500 mg XR tablets and food effect on 2 × 750 mg XR tablets in healthy subjects. Epilepsia49(Suppl. 7), 446 (2008).
   PubMedGoogle Scholar
• Rouits E, Lovern M, Sargentini-Maier M-L, Stockis A. Population pharmacokinetics of levetiracetam extended-release 500 mg tablets. Epilepsia49(Suppl. 7), 451–452 (2008).
   Google Scholar
• Peltola J, Coetzee C, Jimenez F et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia50(3), 406–414 (2009).
   PubMed Web of Science ®Google Scholar
• Schoemaker R, Snoeck E, Stockis A, Otoul C, Sargentini-Maier M-L. Dose–response analysis of levetiracetam extended- and immediate-release formulations in adults with partial onset seizures. Epilepsia49(Suppl. 7), 452–453 (2008).
   Google Scholar
• Richy FF, Banerjee S, Gervasoni C, Grossman P, Helmers S. Safety profile of levetiracetam extended release as compared to immediate release: an indirect comparison using a meta-analytic approach. Epilepsia49(Suppl. 7), 449–450 (2008).
   Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res.83(1), 1–43 (2009).
   PubMed Web of Science ®Google Scholar
• Meador KJ, Pennell PB, Harden CL et al; The HOPE workgroup. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology71(14), 1109–1117 (2008).
   PubMed Web of Science ®Google Scholar